FOXM1 and β-catenin in meningiomas: biomarkers for tumor proliferation and progression

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Egyptian Journal of Pathology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.4103/egjp.egjp_44_21
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis

  2021cited by this paper
• Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management

  2020cited by this paper
• Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma

  2020cited by this paper
• Histological transformation in recurrent WHO grade I meningiomas

  2020cited by this paper
• The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations

  2020cited by this paper
• Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression

  2020cited by this paper
• Forkhead Box M1 promotes the growth and tube formation of human malignant meningioma cells via the aryl hydrocarbon receptor signaling pathway.

  2020cited by this paper
• Epigenetic demethylation of sFRPs, with emphasis on sFRP4 activation, leading to Wnt signalling suppression and histone modifications in breast, prostate, and ovary cancer stem cells.

  2019cited by this paper
• Molecular and translational advances in meningiomas.

  2019cited by this paper
• Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors

  2019cited by this paper
• Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation

  2018cited by this paper
• P02.01 Altered FoxM1 expression contributes to the meningioma malignancy and can be a critical target for the tumor progression

  2018cited by this paper
• Expression of N-cadherin and β-catenin in human meningioma in correlation with peritumoral edema

  2018cited by this paper
• Expression levels of β-catenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study

  2017cited by this paper
• Integrated genomic analyses of de novo pathways underlying atypical meningiomas

  2017cited by this paper
• FoxM1 is a promising candidate target in the treatment of breast cancer

  2017cited by this paper
• Case-Based Review: meningioma.

  2016cited by this paper
• Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling

  2016cited by this paper
• Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence.

  2016cited by this paper
• Wnt‐induced deubiquitination FoxM1 ensures nucleus β‐catenin transactivation

  2016cited by this paper
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

  2016cited by this paper
• Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications

  2016cited by this paper
• Glioblastoma multiforme formation and EMT: role of FoxM1 transcription factor.

  2015cited by this paper
• Mitotic Index is an Independent Predictor of Recurrence‐Free Survival in Meningioma

  2015cited by this paper
• MELK-Dependent FOXM1 Phosphorylation is Essential for Proliferation of Glioma Stem Cells

  2013cited by this paper
• The Potential Involvement of E-cadherin and β-catenins in Meningioma

  2010cited by this paper
• Characterization of a novel type of adherens junction in meningiomas and the derived cell line HBL-52

  2008cited by this paper
• Genetic changes of CDH1, APC, and CTNNB1 found in human brain tumors.

  2007cited by this paper
• Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer

  2005cited by this paper

• Application of the Mass Spectrometry–High‐Throughput Technique Over the Immunohistochemical Analysis for Human Brain Tumor Diagnosis and Prognosis: Insights Into Biomarkers' Identification for the Case Study of Grade IV Astrocytomas and Meningiomas

  2025cites this paper
• Clinicopathological Impact of FOXM1 and MMP-9 Immunohistochemical Expression in Different Grades of Intracranial Meningioma

  2024cites this paper